欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

您的位置: 首页 / 单抗抑制剂 / Rituximab

CAS No.: 174722-31-7

Rituximab

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that targets CD20, a B-cell-specific surface antigen.

规格 价格 库存
5 mg RMB 5208 产品咨询

描述

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that targets CD20, a B-cell-specific surface antigen. It was the first monoclonal anti-CD20 antibody to be approved for medical use in human diseases. It was initially licensed for non-Hodgkin‟s lymphoma and then made available for chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. RTX was also successfully used off-label to treat neuromyelitis optica spectrum disorders, MS, myasthenia gravis, autoimmune encephalitis, autoimmune neuropathies, and myopathies.

同义词

Rituxan

参考

Rituximab. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); July 20, 2020.|https://pubmed.ncbi.nlm.nih.gov/30000857/

Tian X, Chen C, Ma L, et al. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis [published online ahead of print, 2020 Jul 10]. J Neuroimmunol. 2020;347:577317. doi:10.1016/j.jneuroim.2020.577317|https://pubmed.ncbi.nlm.nih.gov/32731048/

大规格询价

号为必填项

姓名: 邮箱: 手机号:
留言:
   提交
联系
我们